Nestle will pay US$2 billion to buy the remaining stake in Aimmune Therapeutics Inc, gaining full ownership of the first US-approved peanut allergy treatment. <br /> <br />WATCH MORE: https://thestartv.com/c/news<br />SUBSCRIBE: https://cutt.ly/TheStar<br />LIKE: https://fb.com/TheStarOnline<br />
